Michael Klichinsky News Today

First lead candidate to address a solid tumor indication with significant unmet medical need Supportive pre-clinical proof of concept data reported at SITC 2023 that demonstrated feasibility,...

The HER2-directed CAR-macrophage therapy CT-0508 displayed a tolerable safety profile and signs of antitumor activity in patients with a variety of solid tumors.

Carisma Therapeutics Inc. will present findings at the 8th Annual CAR-TCR Summit from its Phase 1 clinical trial of the Companys lead product candidate, CT-0508, a human epidermal growth factor...

Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508   New translational analyses combining group 1 & group 2 continue to support...

PHILADELPHIA, Aug. 24, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced...

Study is designed to evaluate the potential for a synergistic effect of CAR-M therapy in combination with KEYTRUDA® PHILADELPHIA, June 28, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) (

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

CARM | Complete Carisma Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 997 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Carisma Therapeutics to related businesses based on the strength of its earnings, analyst recommendations, profitability, risk, institutional ownership, valuation and dividends. Earnings & Valuation This […]

/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and...